Kintor Pharmaceutical Ltd Ordinary Shares 09939
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 0.94
- Day Range
- HKD 0.94–1.04
- 52-Week Range
- HKD 0.81–5.83
- Bid/Ask
- HKD 0.96 / HKD 0.97
- Market Cap
- HKD 429.60 Mil
- Volume/Avg
- 1.5 Mil / 12.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 225
- Website
- https://www.kintor.com.cn
Comparables
Valuation
|
Metric
|
09939
|
06855
|
06978
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.84 | 75.38 | 9.06 |
Price/Sales | — | 19.88 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
09939
|
06855
|
06978
|
|---|---|---|---|
Quick Ratio | 2.66 | 2.73 | 1.77 |
Current Ratio | 4.89 | 2.74 | 1.81 |
Interest Coverage | −54.22 | −9.36 | −39.58 |
Quick Ratio
09939
06855
06978
Profitability
|
Metric
|
09939
|
06855
|
06978
|
|---|---|---|---|
Return on Assets (Normalized) | −29.60% | −30.37% | −26.86% |
Return on Equity (Normalized) | −42.85% | −142.24% | −49.11% |
Return on Invested Capital (Normalized) | −34.63% | −35.31% | −33.40% |
Return on Assets
09939
06855
06978
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qjmjttnhbk | Wphq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hwkftrmcr | Qwwvjs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mmqsxrnfz | Sywyx | $97.8 Bil | |
MRNA
| Moderna Inc | Fzjtrhff | Ybfvh | $38.8 Bil | |
ARGX
| argenx SE ADR | Nbqxnwn | Jryf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kqlcnnnrg | Drckv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qpwbjhzw | Hdsrtz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zwfzhtfm | Ccjrx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sptxpchq | Dzkxt | $12.5 Bil | |
INCY
| Incyte Corp | Cfbhkzqp | Vbnxvcb | $11.5 Bil |